重组干扰素α2b雾化吸入在小儿毛细支气管炎治疗中的临床疗效观察

李德优 许景怀 刘明凤

[摘要]目的 探討重组干扰素α2b雾化吸入在小儿毛细支气管炎治疗中的临床效果。方法 选择2019年10月～2020年1月在我院进行治疗的80例小儿毛细支气管炎患儿作为研究对象，依据随机对照原则分为对照组与观察组，各40例。对照组给予布地奈德+特布他林雾化治疗，观察组在对照组治疗基础上加用重组干扰素α2b雾化治疗。比较两组的临床疗效、相关症状消失时间、住院时间及住院费用。结果 观察组的治疗总有效率为100.00%，高于对照组的85.00%，差异有统计学意义（P<0.05）;观察组的发热消失时间、咳嗽消失时间、喘息消失时间、肺部哮鸣音及湿啰音消失时间均短于对照组，差异有统计学意义（P<0.05）;观察组的住院时间短于对照组，住院费用低于对照组，差异有统计学意义（P<0.05）。结论 重组干扰素α2b雾化吸入在小儿毛细支气管炎治疗中的临床效果较好，可以改善患儿的临床症状，缩短患儿的症状消失时间。

[关键词]重组干扰素α2b;雾化吸入;小儿毛细支气管炎;临床疗效

[中图分类号] R725.6          [文献标识码] A          [文章编号] 1674-4721（2020）8（a）-0121-03

Clinical efficacy observation of Recombinant Interferon α2b for aerosol inhalation in the treatment of bronchiolitis in children

LI De-you   XU Jing-huai   LIU Ming-feng

Department of Pediatrics， Pingxiang Maternal and Child Health Hospital， Jiangxi Province， Pingxiang   337000， China

[Abstract] Objective To investigate the clinical effect of Recombinant Interferon α2b for aerosol inhalation in the treatment of bronchiolitis in children. Methods A total of 80 cases of children with bronchiolitis treated in our hospital from October 2019 to January 2020 were selected as the research objects. According to the principle of random control， they were divided into the control group and the observation group， 40 cases in each group. The control group was given Budesonide + Terbutaline Atomization treatment， and the observation group was given Recombinant Interferon α2b for aerosol inhalation treatment on the basis of the control group. The clinical efficacy， the disappearance time of related symptoms， hospitalization time and hospitalization expenses were compared between the two groups. Results The total effective rate of the observation group was 100.00%， which was higher than 85.00% of the control group， there was significant difference （P<0.05）. The disappearance time of fever， cough， panting， wheezing rale， moist rale of the observation group were shorter than those of the control group， and the differences were significant （P<0.05）. The hospitalization time of the observation group was shorter than that of the control group， and the hospitalization cost of the observation group was lower than that of the control group， and the differences were significant （P<0.05）. Conclusion Recombinant interferon α2b for aerosol inhalation has a good clinical effect in the treatment of bronchiolitis in children， which can improve the clinical symptoms of children and shorten the disappearance time of symptoms in children.

[Key words] Recombinant Interferon α2b; Aerosol inhalation; Pediatric bronchiolitis; Clinical efficacy

小儿毛细支气管炎是一种儿童较常见的下呼吸道感染，多发于冬春季节，主要由呼吸道合胞病毒、鼻病毒、副流感病毒、腺病毒、人类偏肺病毒等引起，病变主要发生在细小支气管炎，以阵发性咳嗽、喘憋、呼吸急促、肺部喘鸣音、三凹征为主要临床特点，严重者可发生呼吸衰竭、心力衰竭和中毒性脑病等并发症[1]。本病常规治疗以保持呼吸道通畅、减少气道阻塞及分泌物渗出、改善肺通气和换气功能为主，但目前并无有效的抗病毒药物[2-3]。干扰素为机体在病毒感染后产生的重要细胞因子，具有抗病毒和免疫调节的双重作用，且雾化吸入可直达患处，减轻患儿痛苦[4-5]。本研究通过观察干扰素雾化吸入联合布地奈徳、特布他林雾化吸入治疗在小儿毛细支气管炎中的临床效果，旨在为临床诊治小儿毛细支气管炎提供参考，现报道如下。……